Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.

摘要: To examine associations between the UGT2B17 gene deletion and exemestane metabolites, commonly reported side effects (fatigue, hot flashes, joint pain) among postmenopausal women participating in MAP.3 chemoprevention trial. The analytical samples for analysis comprised 1752 on 1721 placebo; metabolite included 1360 with one-year serum samples. Both metabolites were measured blood. conceptualized as a ratio (17-DHE-Gluc:17-DHE). Symptoms assessed using CTCAE v4.0 at approximately 1-year intervals. Log-binomial regression was used to deletion, each effect 1 up 5-year follow-up, adjusting potential confounders. Among individuals (i.e., lower detoxification), higher risk of severe fatigue (RR = 2.59 95% CI: 1.14–5.89) observed follow-up. placebo, those had any (RR = 1.39, 1.02–1.89) year 1. A (poor detoxification) associated fatigue, flashes pain (fatigue: RR = 1.89, 1.16–3.09; flashes: RR = 1.77, 1.40–2.24; pain: RR = 2.05, 1.35–3.12); similar Variation metabolism through UGT2B17-mediated pathway is subsequent symptoms MAP.3.